Search PubMed⌕ Search

Biomedical subjects

S C Taylor

Publications and source records attributed to S C Taylor.

66 records · Page 4Linked to original sources
PubMed1986

Effects of chronic treatment with benzodiazepine receptor ligands on cortical adrenoceptors.

We report the effects of kindling with the benzodiazepine partial inverse agonist, FG 7142 on adrenoceptor binding in mouse cerebral cortex. Twelve once-daily injections of FG 7142 caused a statistically significant increase in the density of both alpha 2- and beta-adrenoceptor binding sites, seven days after the last injection. Despite the marked effects of FG 7142 on adrenoceptors, there were no changes in either alpha 2- or beta-adrenoceptor binding after prolonged treatment with the benzodiazepine, flurazepam.

Animals↗
PubMed1986

The effects of drugs acting at the GABAA-receptor/ionophore after chemical kindling with the benzodiazepine receptor ligand FG 7142.

Repeated administration of the beta-carboline benzodiazepine receptor ligand FG 7142 produces sensitization to its effects so that full seizures develop (chemical kindling); initially it is only pro-convulsant. The present study investigated alterations in the function of drugs which act at the different sites at the gamma-aminobutyric acid (GABA) benzodiazepine receptor complex, after repeated administration of FG 7142. In FG 7142 kindled mice decreased anticonvulsant and hypothermic effects of the GABA agonist muscimol were observed. The hypothermic effects of the GABA agonist progabide were reduced. In contrast a small increase in the hypothermic effect of pentobarbitone was seen. The convulsant effects of bicuculline and picrotoxin were unaltered when they were given intravenously but marginally increased when they were given by the intraperitoneal route. No changes were seen in the hypothermic effects of these drugs. No significant changes were seen in the convulsant or hypothermic effects of pentylenetetrazol. These results suggest that kindling with FG 7142 may alter GABA receptor function.

Animals↗
PubMed1986

Optimizing the pentetrazol infusion test for seizure threshold measurement.

Seizure thresholds in mice were determined using the pentetrazol infusion method. Concentration of infusate and rate of infusion were varied to assess the optimal parameters for seizure threshold detection. Seizure threshold elevations were produced by flurazepam and threshold decreases by FG 7142. An infusion rate of 1.1 ml min-1 was best for detecting both increases and decreases in threshold. However a concentration of 2.5 mg ml-1 gave optimal measurement of elevations in threshold whereas decreased thresholds were best detected with a concentration of 10 mg ml-1.

Animals↗
PubMed1985

The benzodiazepine antagonist, Ro 15-1788 does not decrease ethanol withdrawal convulsions in rats.

The effects of the benzodiazepine antagonist, Ro 15-1788 on ethanol withdrawal convulsions were investigated in rats. The study originated from recent reports of benzodiazepine binding activity in urine of alcoholics during withdrawal. No alleviation of convulsions was found with Ro 15-1788. This suggested that this component of the withdrawal syndrome is not due to endogenous production of a benzodiazepine inverse agonist (contragonist), as Ro 15-1788 prevents the action of this type of compound.

Animals↗
PubMed1985

A benzodiazepine agonist and contragonist have hypothermic effects in rodents.

The effects on body temperature of the benzodiazepine contragonists FG 7142 (N-methyl-beta-carboline-3-carboxamide) and DMCM (methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate), the benzodiazepine antagonist Ro 15-1788 (ethyl-8-fluoro-5,6-dihydro-5-methyl-7-oxo-4H-imidazo-(1,5-a)(1,4)benzod iazepin e -3-carboxylate) and the benzodiazepine agonist, flurazepam, were investigated in mice. Both of the contragonists and flurazepam reduced the body temperature. The antagonist Ro 15-1788 did not alter body temperature alone but significantly antagonised the effects of FG 7142 and of flurazepam. The effects of the latter two drugs on locomotor activity in animals in a familiar environment were also investigated. Flurazepam reduced the activity counts in these circumstances but FG 7142 did not cause a significant change, at doses which considerably reduced body temperature. The drug FG 7142 also reduced the body temperature in rats. The effects on body temperature of the benzodiazepine contragonists and flurazepam were unusual in that they were changes in the same direction, both antagonised by Ro 15-1788. However, they differed in that while the effects of flurazepam on locomotor activity might contribute to its hypothermic effect this did not appear to be the case for FG 7142.

Animals↗
PubMed1984

Investigating benzodiazepine receptor function in vivo using an intravenous infusion of DMCM.

A method for measuring seizure thresholds using an intravenous infusion of a convulsant beta-carboline benzodiazepine receptor ligand (DMCM) is reported. Seizure thresholds to DMCM are elevated by the benzodiazepine receptor agonist, flurazepam and antagonist, Ro 15-1788, and the proconvulsant beta-carboline, FG 7142. Various other anticonvulsant also antagonise DMCM seizures. Selectivity for the benzodiazepine/GABA receptor complex is demonstrated since bicuculline and pentylenetetrazol lowered thresholds whereas strychnine and N-methyl DL-aspartate did not.

Animals↗
PubMed1984

Acute and chronic effects of the benzodiazepine receptor ligand FG 7142: proconvulsant properties and kindling.

The effects of the acute and chronic administration of the beta-carboline benzodiazepine receptor ligand, FG 7142 were studied in mice. On acute administration FG 7142 (at doses between 10 and 40 mg kg-1) lowered seizure thresholds to infused pentylenetetrazol (PTZ) but showed an unusual dose-response curve in that higher doses had less effect. The duration of action was considerably longer than that of other beta-carbolines, such as ethyl-beta-carboline-3-carboxylate (beta CCE). During repeated administration, doses of FG 7142 which were initially proconvulsant subsequently produced generalized seizures on average in 60% of animals after 12 once daily treatments. This seemed to be a form of chemical kindling. The effects of different drug administration regimes were studied. Once daily dosage was shown to be the optimum for kindling production, and was therefore used for subsequent experiments. Kindling lasted for at least one month after 12 single once daily doses of 40 mg kg-1 (FG 7142). The administration of the benzodiazepine antagonist Ro 15-1788 concurrent with FG 7142 prevented kindling. When Ro 15-1788 was given to kindled animals along with a challenge dose of FG 7142, it prevented the expression of kindled seizures. These data show that kindling is mediated via the benzodiazepine receptor.

Animals↗
PubMed1981

Virus inhibition assay for measurement of acyclovir levels in human plasma and urine.

A simple microplate virus inhibition assay which measures the levels of acyclovir in plasma and urine samples from patients was developed. The assay is based upon the inhibition of the cytopathic effect of herpes simplex virus type 1 on human fibroblast cells. The extent of inhibition of virus cytopathic effect, caused by dilutions of samples from patients, allowed determination of acyclovir concentrations to be made. The assay, which measured biological activity, could detect acyclovir levels of greater than or equal to 1.0 microM. Peak and valley levels measured in plasma samples from two patients were comparable to values obtained by radioimmunoassay. The assay is simple, rapid, and quantitative, and it can be adapted to routine use for a large number of specimens.

Acyclovir↗
PubMedDate not supplied

Cosmetic problems in skin of color.

Practitioners are confronted with a myriad of cutaneous diseases affecting skin of color. Skin of color, which encompasses the pigmented skin of those of African American, Asian and Hispanic descent is susceptible to several unique and cosmetically disfiguring problems. Acne vulgaris, pseudofolliculitis barbae, postinflammatory hyperpigmentation and photoaging are diseases which commonly necessitate visits to the dermatologist and are of major cosmetic concern for those with skin of color. Effective treatments are needed to quickly resolve the inflammatory lesions of acne and pseudofolliculitis. The number of agents available for the treatment of postinflammatory hyperpigmentation is limited, and some agents are minimally effective. In addition to more effective therapeutic agents, development of enhanced camouflaging techniques are also necessary. Finally, sunscreens which provide more complete protection for skin of color are needed to address the issue of both photoaging and hyperpigmentation. We look to the cosmetic industry to develop new products and to improve currently existing products to address the cosmetic concerns of skin of color.

Humans↗